Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results.

Considering histopatological features (Table 6 ), no significant difference in cg and microvascular inflammation scores (g, ptc, g + ptc) or C4d positivity was observed between patients with functioning and non-functioning grafts at 24 mo in the PE-IVIG-RTX group, despite the fact that patients with non-functioning grafts showed a trend towards a more pronounced chronicity score at diagnosis (median 0.5 in patients with functioning grafts vs 2 in patients with non-functioning grafts; P = 0.29).

also in 53,322 other papers

However, the association between the addition of rituximab or Thymoglobulin to steroids/IVIG with better graft survival did not reach statistical significance.

also in 111,027 other papers